Ahmad Syed S
Ibnsina Academy of Medieval Sciences, Aligarh, India.
Saudi J Ophthalmol. 2020 Nov 22;34(1):45-49. doi: 10.4103/1319-4534.301299. eCollection 2020 Jan-Mar.
Presently the management of glaucoma is limited to lowering of intra-ocular pressure (IOP). Since this modality does not appear to be successful in all cases there is increasing focus on non-IOP lowering medications. Coenzyme Q is a naturally occurring compound similar to vitamins. There are a few reports suggesting the neuroprotective efficacy of this agent in glaucoma models. The present systematic review was undertaken to study the pharmacology, physiology, metabolism and role of Coenzyme Q in glaucoma. An English-language search for relevant items was undertaken using PubMed, Google Scholar, Scopus and other databases. The present review found a positive outcome of Coenzyme Q as a neuroprotectant being reported in all studies. However, the review also found that the majority of studies on Coenzyme Q have been reported by a single group of researchers. In order to have a more wide-ranging impact regarding the efficacy of Coenzyme Q in glaucoma, it would be useful to undertake further multi- center trials.
目前，青光眼的治疗仅限于降低眼压（IOP）。由于这种治疗方式在所有病例中似乎并非都能成功，因此对非降眼压药物的关注日益增加。辅酶Q是一种天然存在的类似维生素的化合物。有一些报告表明该药物在青光眼模型中具有神经保护作用。本系统综述旨在研究辅酶Q在青光眼中的药理学、生理学、代谢及作用。通过PubMed、谷歌学术、Scopus和其他数据库对相关英文文献进行了检索。本综述发现，所有研究均报道辅酶Q作为神经保护剂有积极效果。然而，该综述还发现，关于辅酶Q的大多数研究是由同一组研究人员报道的。为了使辅酶Q治疗青光眼的疗效产生更广泛的影响，开展进一步的多中心试验将是有益的。
